The Latest Breaking News from 10x Genomics

With vast potential, contribution to rare disease discovery and management, and adoption of AI, the genomic research market is thriving. Hence, fundamentally solid genomic research stocks Agilent Technologies (A), Illumina (ILMN), and 10x Genomics (TXG) could be ideal buys. Read more.

10x Genomics stock crashed Thursday after the medtech reported preliminary third-quarter sales that widely missed Street expectations.

TXG stock crashed Friday after genetic technology outlet 10x Genomics preannounced lackluster second-quarter sales.

10x Genomics (NASDAQ:TXG) brought in sales totaling $114.50 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 129.89%, resulting in a loss of $42.41 million.

  10x Genomics (NASDAQ:TXG) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Analysts have provided the following ratings for 10x Genomics (NASDAQ:TXG) within the last quarter:

10x Genomics (NASDAQ: TXG) reported 

10x Genomics (NASDAQ:TXG) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings 10x Genomics missed estimated earnings by 22.58%, reporting an EPS of $-0.38 versus an estimate of $-0.31.

Today I'll analyze and compare Teladoc (TDOC) and 10x Genomics (TXG) to determine which stock is a better buy.